GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after...
GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief Scientific Officer, has been...
— The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) — GAITHERSBURG, Md., July 01, 2025 (GLOBE NEWSWIRE) -- Elutia...
Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope’s impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md., June 26, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT)...
Innovative approach accelerates new product development and testing SILVER SPRING, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the...